BayBio2010 | Life Science Innovation: Drivers and Barriers. Presentations:

• Breakfast Keynote John Kao, Author of "Innovation Nation" and "Jamming: The Art and Discipline of Business" and G. Steven Burrill, CEO, Burrill & Company: “Defining Innovation”
• Luncheon Plenary Jeremy Leffler, COO, BayBio: The Impact of the New Health Care Reform Law on Life Science Companies

Innovation Track (1):

• A fresh look at regulatory strategy – innovating for success
• Strange bedfellows – merging technologies successfully
• Cheap whole genome sequencing: hype or R&D game changer?
• Open innovation: global strategies

Human Resource Track (2):

• Building a high performance team
• Human resource guide to going public
• Human resources strategies: defining the “new norms”

Finance Track (3):

• The rise of option-based and structured deals

Gene Acres 17: Current Challenges, Future Opportunities. Presentations:

• Breakfast Keynote Scott Morrison, National Leader, Life Sciences, Ernst & Young LLP: “Global Financial Crisis: Profound Impact on Biotechnology Business Model”
• Luncheon Plenary James C. Greenwood, President & Chief Executive Officer of the Biotechnology Industry Organization (BIO)
• Luncheon Plenary John P. Walker, Chief Executive Officer, iPierian Inc.: "A Perfect Storm: Altering the Landscape for Biotechnology Innovation”

Real Estate Trends Track (1):

• Reality Check: The State of Real Estate Market
• Real Estate Strategies - Challenges and Opportunities for Tenants and Landlords
• Becoming a Landlord: Maximizing Return on Under Utilized Space

Building & Renovation Track (2):

• Cost Effective Design Solutions for Today's Economy - A Common Sense Approach
• Creating Value by Renovating and Making it Green
• "Just-in-Time"...a Project Delivery State of Mind

Strategic Thinking Track (3):

• Survival Guide: Emergency Preparedness without Breaking a Bank
• A Shrinking Budget: Opportunities and Pitfalls

Business Solutions Track (4):

• Monogram Biosciences: Overcoming a Global Sample Collection Challenge
• SciClone Pharmaceuticals: Win-Win Contract Manufacturing
• Zymogenetics: Driving Scientific Productivity and Cost Reduction Through Asset Management

BayBio2009: Navigating the Storm. Presentations:

• Breakfast Keynote Regis Kelly, Director, The California Institute for Quantitative Biosciences (QB3), University of California, San Francisco: “Enlarging the Public to Private Pipeline”
• Luncheon Plenary Bill Rutter, PhD, CEO and Chairman, Synergenics, LLC: "No Better Time to be in the Biotech Industry. Or, In the Year of the Ox, Don't Get Gored! ”

Survival Strategies Track (1):

• Strategies to Creatively Monetize Your IP Portfolio
• Facing the Storm – Leading with Your Business Partners
• Unconventional Capital: Alternative Financing Options

Product Development Track (2):

• Accelerated Virtual Drug Development

Crisis Management Track (3):

• Human Capital in an Economic Downturn
• Surviving the Storm: Retention Strategies That Are Working!

Company Presentations (4):

• Arcxis Biotechnologies, Tethys Bioscience, Bayhill Therapeutics, Metabolex
• Eureka Therapeutics, Inc., Neugenesis Corporation, Vaxart, Mendel Biotechnology
• KAI Pharmaceuticals, Acologix, Accera, Syntaxin Ltd.
• BiPar Sciences, Target Discovery, Sunesis, KaloBios Pharmaceuticals, Inc.

Gene Acres 16: Managing Risk Leveraging Opportunities. Presentations:

• Breakfast Keynote G. Steven Burrill, CEO, Burrill & Company: “Biotech 2008 – Life Sciences: A 20/20 Vision to 2020”
• Luncheon Plenary Jeffrey H. Cooper, Senior Vice President, Chief Financial Officer, BioMarin Pharmaceutical Inc., Paul J. Hastings, President and Chief Executive Officer, OncoMed Pharmaceuticals, Inc., Philip K. Moody, Chief Financial Officer, Vice President, Finance & Operations, Peplin: "Anatomy of Corporate Success”

Building Track (1):

• 2008 Northern California Life Sciences Real Estate Survey
• “I wish I Would Have Known” – From Site Selection to Grand Opening
• Faster, Cheaper, Better, Greener: Using Integrated Project Delivery and Building Information Modeling to Achieve Outstanding Projects

EH&S Track (2):

• Green Chemistry in Cleantech: Principles and Investment Strategies
• Trash Talk: Understanding the Biotech Laboratory Waste Streamt
• Using L Occupancy in a Multistory Biotech Building

Laboratory Track (3):

• Modular Technology Project Considerations
• Lessons Learned about Laboratory Costs from the CIRM Stem Cell Facility Grant Proposals
• Systems & Tools for Managing Laboratory Equipment and Assets

BayBio2008: Doing Well by Doing Right. Presentations:

• Breakfast Keynote Vinod Khosla: “Mostly Convenient Truths From a Technology Optimist”

Track 1 Commercialization:

• Promoting Cures by Building Online Patient Relationships
• Promises and Pitfalls of Online Clinical Trial Recruitment
• New Business Models for the Changing Commercial Landscape

Track 2 Finance:

• Getting from Lab to Market: Financing Strategies for Biofuel Companies
• Extending the Cash Runway with Venture and Other Forms of Debt
• Creative Finance Vehicles to Fund Growth
• Equity Compensation Strategy Development: Roadmap from pre-IPO to Publicly-Traded

Track 3 Talent:

• Recruiting and Training the Next Generation of Biotechnology Associates
• Developing Successful Project Leaders
• Employee Benefits: The Importance of Shifting Your Focus from Cost to Investment

Track 4 Regulation:

• Three Paths, One Goal: Preparing for Regulatory Submission Compliance
• Changing Landscape of the Regulatory Pathway for Follow-on Biologics
• Global Clinical Trials: Potential Pitfalls of Offshore Trials
• Getting Paid: Managing Your Downstream Risk

Gene Acres15: Ahead of the Curve. Presentations:

• Breakfast Plenary Session Biotechnology State of the Industry Report: Beyond Borders

Track 1 TRENDS:

• Bio-Fuels & Nano-Bio: Coming Soon to a Lab Near You
• Going Green: Profiles of Sustainable Initiatives
• 2007 Bay Area Biotechnology Real Estate Survey

Track 2 GROWTH:

• Gearing up for Manufacturing
• Renovation, Addition, and Adaptive Re-Use for Research Facilities
• Selecting the Right Construction Delivery System for Your Project
• Changing California Building Codes

Track 3 FLEXIBILITY:

• Sustainable Laboratory Design
• Strategies for Facilities Management During M&A or Project Shift

BayBio2007: Innovators and Innovations. Presentations:

• Luncheon Plenary Session Ruth Liu, Associate Secretary, California Health and Human Services Agency: "Looking Ahead: California Healthcare Reform"

Track 1 Policy and Regulations:

• Evolving Regulatory Environment: Challenges and Opportunities
• Sailing to FDA Product Approval: Innovations in the Clinical Trial Paradigm
• Personalized Medicine: Development, Delivery and Regulation

Track 2 Finance:

• Life Sciences Investment: Emerging New Models
• Recent Trends in Life Sciences M&A and Strategic Transactions

Track 3 Successful Organizations:

• Corporate Culture: Creating a Competitive Advantage
• After Acquisition: Bridging Corporate Cultures

Track 4 Commercial Development:

• Fueling the Future
• Gearing Up for Manufacturing

Gene Acres 2006: Presentations:

• Keynote Breakfast Dr. Cynthia Robbins-Roth: "Money, Products, and Politics: Industry Trends and What they Mean for You"
• Closing Plenary Session Reinhard Hanselka: "2007 New California Building, Fire and Mechanical Codes"

Track 1:

• Planning for Proper Laboratory Airflow
• Biocontainment in Facility and Laboratory Environments

Track 2:

• The Pro’s and Con’s of Modular Buildings
• Getting the Lab You Want, version 2.0

Track 3:

• Staying In Business After Disaster
• Maintenance – Are You Compliant?
• 2006 Bay Area Biotechnology Real Estate Survey

BayBio2006 Presentations:

• Fred Frank: "Global Competitiveness and Global Finance for the Life Sciences Industry"
• Slides (330 KB PDF)
• Speech (400 KB PDF)

Gene Acres 2005 Presentations:

• G. Steven Burrill “Biotech 2006 —What’sReally Going to Happen” (2.1 MB PDF)
• “2005 Bay Area Biotechnology Real Estate Survey” (900 KB PDF)

Additional Presentations:

• Radford Surveys Northern California biotech compensation and employment trends. November 4, 2004.
  
• VCynic Syndicate An insider perspective on venture capitalists' decision making. February 15, 2005.